Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
About this study
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
- Condition
- Localized Prostate Carcinoma
- Tested
- High dose rate prostate brachytherapy
- Sponsor
- British Columbia Cancer Agency
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 15
- Minimum age: 18 years
- Study condition: Localized Prostate Carcinoma
- Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
- Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
- ECOG 0-1
- Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \< 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml)
- Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA \< 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density \> 0.2 ng/cc,
- Selected intermediate risk patients not defined above
- T1c/T2a
- PSA \< 10 and Gleason 4+3
- PSA \> 10 (\< 20) and Gleason 3+4
- PSA 10-15 ng/ml and Gleason 4+3 and \< 33% cores involved
- Max tumor length in any core 10 mm
- No androgen deprivation therapy (ADT)
- Signed study specific informed consent.
Exclusion 5
- Prior radical surgery for carcinoma of the prostate,
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer,
- Claustrophobic or unable to undergo MRI
- Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease
Where
1 site, 1 recruiting
British Columbia Cancer Center for the Southern Interior
Kelowna, British Columbia, Canada
Contact
-
Juanita M Crook, MD
250 712 3958 jcrook@bccancer.bc.ca
Potential match only. Final eligibility is determined by the study team.